Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States

• Autores principales: Ching‐Yu Wang (Autor), Phuong N. Pham (Autor), Sarah Kim (Autor), Karthik Lingineni (Autor), Stephan Schmidt (Autor), Vakaramoko Diaby (Autor), Joshua Brown (Autor)
• Formato: Libro
• Publicado: Wiley, 2020-03-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Generic entry of newer anticoagulants is expected to decrease the costs of atrial fibrillation management. However, when making switches between brand and generic medications, bioequivalence concerns are possible. The objectives of this study were to predict and compare the lifetime cost‐effectivene...